4D Molecular Therapeutics (FDMT) EBT Margin (2020 - 2026)
4D Molecular Therapeutics (FDMT) posted quarterly EBT Margin of 3114.9% for Q1 2026, up 35002081.0% year-over-year from N/an in Q1 2025, and down 14809.3% quarter-over-quarter from 21.18% in Q4 2025.
4D Molecular Therapeutics (FDMT) EBT Margin (2020 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported EBT Margin for 7 consecutive years, with 3114.9% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT Margin rose 35002081.0% year-over-year to 3114.9%; the TTM figure through Mar 2026 stood at 286.32% (up 97098759.0% YoY), while the FY2025 annual figure was 350.46%, up 78039278.0% from the prior year.
- EBT Margin retreated to 3114.9% in Q1 2026 per FDMT's latest filing, from 21.18% in the prior quarter.
- Across five years, EBT Margin topped out at 174063.16% in Q4 2023 and bottomed at 5055000.0% in Q4 2024.
- Historically, EBT Margin has averaged 567804.6% across 5 years, with a median of 21127.78% in 2022.
- Annual changes were most pronounced in 2024 — EBT Margin sank 522906316 bps — and 2025, when it surged 505502118 bps.
- 4D Molecular Therapeutics' EBT Margin stood at 2428.39% in 2022, then jumped by 7268 bps to 174063.16% in 2023, then plunged by 3004 bps to 5055000.0% in 2024, then soared by 100 bps to 21.18% in 2025, then sank by 14809 bps to 3114.9% in 2026.
- Business Quant data shows FDMT's EBT Margin at 3114.9% in Q1 2026, 21.18% in Q4 2025, and 95417.78% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | 4D Molecular Therapeutics | 856.62 Mn | 495.28 Mn | - | -2,578.29% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2,578.29% |
| Mar 31, 2026 | -3,114.90% |
| Dec 31, 2025 | 21.18% |
| Sep 30, 2025 | -95,417.78% |
| Jun 30, 2025 | -599,246.67% |
| Mar 31, 2025 | -353,135.71% |
| Dec 31, 2024 | -5,055,000.00% |
| Sep 30, 2024 | -2,598,466.67% |
| Jun 30, 2024 | -909,000.00% |
| Mar 31, 2024 | -139,503.57% |
| Dec 31, 2023 | 174,063.16% |
| Sep 30, 2023 | -143.95% |
| Jun 30, 2023 | -21,454.39% |
| Mar 31, 2023 | -16,541.28% |
| Dec 31, 2022 | -2,428.39% |
| Sep 30, 2022 | -9,463.80% |
| Jun 30, 2022 | -21,127.78% |
| Mar 31, 2022 | -2,717.72% |
| Dec 31, 2021 | -28,560.87% |
| Sep 30, 2021 | -3,479.65% |